These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Trial is partly outside EEC 2007-000498-42 A double-blind, randomised efficacy and safety study of taliglucerase alfa enzyme replacement therapy in children and adolescents with Gaucher disease (non-neuronopathic and chronic neuronopathic) 2009-09-10 bad-data
Trial is partly outside EEC 2008-005825-12 A multi-centre, open-label, switchover trial to assess safety and efficacy of taliglucerase alfa in adult and paediatric patients with Gaucher disease who are currently being treated with imiglucerase... 2013-01-14 bad-data
Trial is partly outside EEC 2008-005826-35 A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease 2013-02-14 bad-data
Ongoing 2011-003676-37 A Multicenter Extension Study of Taliglucerase alfa in Pediatric Subjects with Gaucher Disease not-yet-due
Ongoing 2011-003685-32 A Multicenter Extension Study of Taliglucerase alfa in Adult Subjects with Gaucher Disease not-yet-due
Exempt, with results 2012-004786-40 A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for... 2015-05-18 not-yet-due
Exempt, with results 2013-002554-78 An Extension of Phase 1/2, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Eve... 2016-02-17 not-yet-due
Exempt 2014-005544-18 A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients. not-yet-due
Ongoing 2016-000378-38 A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase B... not-yet-due
Not reported 2016-000509-35 An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients with Active Mild to Moderate Ulcerative Colitis 2018-04-04 due-trials
Listed as ongoing, but also has a completion date 2016-001318-11 An Open Label Study of the Safety and Efficacy of PRX 102 in Patients with Fabry Disease Currently Treated With REPLAGAL® (Agalsidase alfa) 2020-01-09 bad-data
Listed as ongoing, but also has a completion date 2017-001528-23 A Phase 3, Open Label, Switch Over Study to Assess the Safety, Efficacy and Pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks for 52 weeks i... 2020-07-02 bad-data
Ongoing 2018-001148-67 Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease not-yet-due
Ongoing 2018-001947-30 Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease not-yet-due